HomeInsightsStock Comparison

Laurus Labs Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Laurus Labs Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Apr 27, 2025

Key Highlights

  • The Latest Trading Price of Laurus Labs Ltd is ₹ 625.4 as of 25 Apr 15:30.
  • The P/E Ratio of Laurus Labs Ltd changed from 13.5 on March 2020 to 131.5 on March 2024 . This represents a CAGR of 57.66% over 5 yearsThe P/E Ratio of Sun Pharmaceuticals Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Laurus Labs Ltd changed from ₹ 3449 crore on March 2020 to ₹ 21113 crore on March 2024 . This represents a CAGR of 43.67% over 5 yearsThe Market Cap of Sun Pharmaceuticals Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Laurus Labs Ltd for the Mar '25 is ₹ 1778 crore as compare to the Dec '24 revenue of ₹ 1424 crore. This represent the growth of 24.88% The revenue of Sun Pharmaceuticals Industries Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 14141 crore. This represent the decline of -100%.
  • The ebitda of Laurus Labs Ltd for the Mar '25 is ₹ 479.17 crore as compare to the Dec '24 ebitda of ₹ 294.57 crore. This represent the growth of 62.67% The ebitda of Sun Pharmaceuticals Industries Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 4158 crore. This represent the decline of -100%.
  • The net profit of Laurus Labs Ltd changed from ₹ 28.4 crore to ₹ 233.87 crore over 8 quarters. This represents a CAGR of 186.96% The net profit of Sun Pharmaceuticals Industries Ltd changed from ₹ 2013 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Laurus Labs Ltd changed from 10.13 % on March 2020 to 19.27 % on March 2024 . This represents a CAGR of 13.72% over 5 yearsThe Dividend Payout of Sun Pharmaceuticals Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Laurus Labs Ltd

  • Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.
  • The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others.
  • The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh.
  • Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America.

About Sun Pharmaceuticals Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Laurus Labs Ltd News Hub

News

Board of Laurus Labs recommends 2nd interim dividend

Laurus Labs announced that the Board of Directors of the Company at its meeting held on 24...

Read more

24 Apr 2025 16:52

News

Laurus Lab Q4 PAT soars to Rs 234 cr

Revenue from operations jumped 19.49% YoY to Rs 1,720.30 crore in Q4 FY25. Profit before t...

Read more

24 Apr 2025 17:20

News

Laurus Labs declare Quarterly Result

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 April 2025....

Read more

11 Apr 2025 09:55

News

Laurus Labs to acquire 26% stakes in Kurnool Renewables for Rs 35 cr

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar ...

Read more

28 Mar 2025 15:15

News

Board of Laurus Labs approves investment of Rs 83.30 cr in KRKA Pharma

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of a...

Read more

06 Mar 2025 19:44

News

Laurus Labs Ltd soars 3.43%, up for third straight session

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2,...

Read more

05 Mar 2025 13:06

Sun Pharmaceuticals Industries Ltd News Hub

News

Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publica...

Read more

24 Apr 2025 09:12

News

Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the bra...

Read more

07 Apr 2025 09:07

News

Sun Pharma launches Fexuprazan tablets 40 mg in India

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosi...

Read more

07 Apr 2025 10:23

News

Sun Pharma completes acquisition of Antibe Therapeutics Inc., Canada

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., ...

Read more

18 Mar 2025 15:01

News

Sun Pharma gains as arm acquires Antibe Therapeutics for $4.5 Million

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty...

Read more

18 Mar 2025 12:53

News

Sun Pharmaceuticals Industries Ltd soars 0.96%, gains for fifth straight session

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is q...

Read more

17 Mar 2025 13:00

SWOT Analysis Of Laurus Labs Ltd

Strength

6

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Sun Pharmaceuticals Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Laurus Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Laurus Labs Ltd and Sun Pharmaceuticals Industries Ltd

Which company has a larger market capitalization, Laurus Labs Ltd or Sun Pharmaceuticals Industries Ltd?

Market cap of Laurus Labs Ltd is 33,724 Cr while Market cap of Sun Pharmaceuticals Industries Ltd is 428,725 Cr

What are the key factors driving the stock performance of Laurus Labs Ltd and Sun Pharmaceuticals Industries Ltd?

The stock performance of Laurus Labs Ltd and Sun Pharmaceuticals Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Laurus Labs Ltd and Sun Pharmaceuticals Industries Ltd?

As of April 27, 2025, the Laurus Labs Ltd stock price is INR ₹625.4. On the other hand, Sun Pharmaceuticals Industries Ltd stock price is INR ₹1786.85.

How do dividend payouts of Laurus Labs Ltd and Sun Pharmaceuticals Industries Ltd compare?

To compare the dividend payouts of Laurus Labs Ltd and Sun Pharmaceuticals Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions